Paloma Partners Management Co Buys Shares of 3,250 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Paloma Partners Management Co bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 1st quarter, Holdings Channel reports. The firm bought 3,250 shares of the biopharmaceutical company’s stock, valued at approximately $486,000.

Several other large investors have also recently made changes to their positions in the stock. Commerce Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 1.7% in the 4th quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after acquiring an additional 77 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in Alnylam Pharmaceuticals by 7.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 89 shares during the period. Metis Global Partners LLC increased its stake in Alnylam Pharmaceuticals by 2.2% during the 4th quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after buying an additional 94 shares during the period. Lindbrook Capital LLC increased its stake in Alnylam Pharmaceuticals by 37.2% during the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 100 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in Alnylam Pharmaceuticals by 1.1% during the 1st quarter. Daiwa Securities Group Inc. now owns 10,921 shares of the biopharmaceutical company’s stock worth $1,632,000 after buying an additional 116 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ALNY shares. Cantor Fitzgerald upped their target price on shares of Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Eight research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $256.73.

Insider Buying and Selling

In related news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the firm’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the sale, the executive vice president now owns 14,181 shares in the company, valued at approximately $3,275,669.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Insiders sold a total of 74,450 shares of company stock worth $15,287,984 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.6 %

NASDAQ:ALNY traded up $1.44 during trading hours on Monday, reaching $236.28. 455,953 shares of the company’s stock were exchanged, compared to its average volume of 879,335. The firm has a market capitalization of $29.89 billion, a price-to-earnings ratio of -88.16 and a beta of 0.37. The company has a 50-day moving average of $200.71 and a 200 day moving average of $172.70. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $263.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The firm’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.40) EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.